Chemical Structure (Besponsa 01)
Besponsa Injection, Powder, Lyophilized, For Solution
Product Images NDC 0008-0100
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Besponsa (NDC 0008-0100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Besponsa 02)
This is a survival analysis study comparing two treatments, BESPONSA and Investigator's Choice of Chemotherapy. The survival probability and hazard ratio are reported. The number of patients at risk is shown for each treatment arm over time. The median survival time was 7.7 months for BESPONSA and 6.2 months for Investigator's Choice of Chemotherapy. The hazard ratio was 0.75 with a 97.5% confidence interval [0.57-0.99].*
Pfizer Logo (Besponsa 03)
This is a description indicating that a company called Wyeth Pharmaceuticals LLC manufactured a product. It is mentioned that the company is a subsidiary of Pfizer Inc in Philadelphia with postcode 19101.*
Principal Display Panel (0.9 mg Vial Label)
NE @ NDC 0008-0100-01 is a refrigerated vial, which should be stored at a temperature between 2°C to 8°C (36°F to 46°F), in its original carton to protect it from light. It is prescribed for the treatment of Inotuzumab Ozogamicin. The medication should not be frozen and instructions for preparation and administration can be found in the prescribing information. The concentration of the injection is 0.25 mg/mL when reconstituted with 4mL sterile water for injection. The medication is manufactured by Wyeth Pharmaceuticals LLC and is for intravenous infusion only. Discard unused portion.*
Principal Display Panel (0.9 mg Vial Carton)
BESPONSA is a prescription medication in the form of an injection used as a treatment for certain types of Leukemia. The medication comes in the form of single-dose vials each containing 0.9mg/vial of inotuzumab ozogamicin. The vials need to be refrigerated at 2°C to 8°C and should be discarded after use. One should not use the medication if it contains any visible particles or discoloration. The medication should only be used under a physician's supervision.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
